Please assess the completion status of the following clinical trial:

Trial Title: Suicide Plus Immune Gene Therapy for Advanced Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically and / or cytologically confirmed melanoma.~* Patients progressed or are intolerant to conventional systemic treatments.~* Patients that are not candidates for surgery under oncologic criteria (complete resection).~* Performance status (ECOG) 0 or 1.~* Patients with life expectancy greater than 6 months.~* Patients with at least one accessible target lesion for gene inoculation (superficial localizations of the primary tumor, satelitosis, subcutaneous or accessible lymph node metastasis).~* Patients with measurable disease (according to RECIST 1.1 criteria, irrespective of the target lesion chosen for suicide gene inoculation)~* Patients with signed informed consent.~Exclusion Criteria:~* Patients with uncontrolled cardiovascular disease~* Patients with uncontrolled respiratory disease.~* Patients with uncontrolled immune disease.~* Patients with glucocorticoids or immunosuppressive drugs or agents with immunomodulatory activity (except non-steroidal anti-inflammatory agents) up to 2 weeks before treatment.~* Patients performing other experimental therapies.~* Patients who are pregnant or breastfeeding.~* Patients undergoing concurrent chemotherapy or radiation therapy.~* Uncontrolled diabetes.~* Patients with active diagnosis of other malignant neoplasms.~* HIV-positive patients.~* Uncontrolled thyroid abnormality.~* Patients with significant medical morbidity.~* Patients with a history of allergic reactions to chemicals or similar to those used in this study.~* Metastasis in the central nervous system.~* Laboratory eligibility criteria excluded:~  * Hemoglobin: \<8 g / dL, leukocytes: \<3,000 / mm3, platelets: \<100,000 / mm3, neutrophils: \<1000 / mm3, hematocrit: \<25%. bilirubin\> 2.0 mg / dL, GOT or GPT: 2.5 times\> than normal upper institutional limit (ULN), alkaline phosphatase: 2 times\> ULN, creatinine\> 2.0 mg / dL, creatinine clearence : \<60 ml / min / 1.73 m2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suicide plus immunogene therapy (Type: EXPERIMENTAL): Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.

Based on this trial design, predict the completion outcome and termination type (if applicable).